These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 36537908)

  • 61. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
    Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
    Wang Y; Jain P; Locke FL; Maurer MJ; Frank MJ; Munoz JL; Dahiya S; Beitinjaneh AM; Jacobs MT; Mcguirk JP; Vose JM; Goy A; Andreadis C; Hill BT; Dorritie KA; Oluwole OO; Deol A; Paludo J; Shah B; Wang T; Banerjee R; Miklos DB; Rapoport AP; Lekakis L; Ghobadi A; Neelapu SS; Lin Y; Wang ML; Jain MD
    J Clin Oncol; 2023 May; 41(14):2594-2606. PubMed ID: 36753699
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
    Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
    Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
    Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
    Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
    Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Enabling CAR T-cell therapies for HIV-positive lymphoma patients - A call for action.
    Hattenhauer ST; Mispelbaum R; Hentrich M; Boesecke C; Monin MB
    HIV Med; 2023 Sep; 24(9):957-964. PubMed ID: 37322863
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.
    Duarte C; Kamdar M
    Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390802. PubMed ID: 37098236
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
    Pennisi M; Jain T; Santomasso BD; Mead E; Wudhikarn K; Silverberg ML; Batlevi Y; Shouval R; Devlin SM; Batlevi C; Brentjens RJ; Dahi PB; Diamonte C; Giralt S; Halton EF; Maloy M; Palomba ML; Sanchez-Escamilla M; Sauter CS; Scordo M; Shah G; Park JH; Perales MA
    Blood Adv; 2020 Feb; 4(4):676-686. PubMed ID: 32084260
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
    Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
    Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
    Wang M; Siddiqi T; Gordon LI; Kamdar M; Lunning M; Hirayama AV; Abramson JS; Arnason J; Ghosh N; Mehta A; Andreadis C; Solomon SR; Kostic A; Dehner C; Espinola R; Peng L; Ogasawara K; Chattin A; Eliason L; Palomba ML
    J Clin Oncol; 2024 Apr; 42(10):1146-1157. PubMed ID: 38072625
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
    Kurte MS; Siefen AC; Jakobs F; von Tresckow B; Reinhardt HC; Kron F
    Eur J Haematol; 2023 Dec; 111(6):895-908. PubMed ID: 37644352
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
    Fusaroli M; Isgrò V; Cutroneo PM; Ferrajolo C; Cirillo V; Del Bufalo F; Raschi E; Poluzzi E; Trifirò G
    Drug Saf; 2022 Aug; 45(8):891-908. PubMed ID: 35829913
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
    Khvorost D; Kendall B; Jazirehi AR
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.
    Ogasawara K; Lymp J; Mack T; Dell'Aringa J; Huang CP; Smith J; Peiser L; Kostic A
    Clin Pharmacol Ther; 2022 Jul; 112(1):81-89. PubMed ID: 35156195
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?].
    Bücklein V; von Tresckow B; Subklewe M
    Dtsch Med Wochenschr; 2024 May; 149(11):630-637. PubMed ID: 38749439
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
    Bastos-Oreiro M; Gutierrez A; Reguera JL; Iacoboni G; López-Corral L; Terol MJ; Ortíz-Maldonado V; Sanz J; Guerra-Dominguez L; Bailen R; Mussetti A; Abrisqueta P; Hernani R; Luzardo H; Sancho JM; Delgado-Serrano J; Salar A; Grande C; Bento L; González de Villambrosía S; García-Belmonte D; Sureda A; Pérez-Martínez A; Barba P; Kwon M; Martín García-Sancho A
    Front Immunol; 2022; 13():855730. PubMed ID: 35911769
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
    Kuhnl A; Kirkwood AA; Roddie C; Menne T; Tholouli E; Bloor A; Besley C; Chaganti S; Osborne W; Norman J; Gibb A; Sharplin K; Cuadrado M; Correia de Farias M; Cheok K; Neill L; Latif AL; González Arias C; Uttenthal B; Jones C; Johnson R; McMillan A; Sanderson R; Townsend W
    Br J Haematol; 2023 Jul; 202(1):65-73. PubMed ID: 37082780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.